Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding.

Stass, Heino; Ince, Ibrahim; Grossmann, Ulrike; Weimann, Boris; Willmann, Stefan

Stass, Heino; Ince, Ibrahim; Grossmann, Ulrike; Weimann, Boris; Willmann, Stefan.

Afiliação

Stass H; Bayer AG, Clinical PK CV, Research & Development, Pharmaceuticals, Building 0431, Wuppertal, 42096, Germany. heino.stass@bayer.com.
Ince I; Research & Development, Pharmaceuticals, Bayer AG, Building B106, Leverkusen, 51368, Germany.
Grossmann U; Clinical Development & Operations, Bayer AG, Building P300, Müllerstrasse 178, Berlin, 13353, Germany.
Weimann B; Chrestos Concept GmbH & Co. KG, Essen, Germany.
Willmann S; Bayer AG, Clinical PK CV, Research & Development, Pharmaceuticals, Building 0431, Wuppertal, 42096, Germany.

AAPS J ; 24(5): 92, 2022 08 24.

Article em En | MEDLINE | ID: mdl-36002604

Assuntos

Doença de Chagas; Nifurtimox; Doença de Chagas/tratamento farmacológico; Criança; Ensaios Clínicos Fase III como Assunto; Humanos; Nifurtimox/efeitos adversos; Nifurtimox/uso terapêutico

Palavras-chave

efficacy; exposure; nifurtimox; pediatric; safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Chagas / Nifurtimox Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google